Join
Live feed
·
PRReleasevia Quantisnow
Harpoon Therapeutics Inc. logo

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

ByQuantisnow·Wall Street's wire, on your screen.
HARP· Harpoon Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HARP (Harpoon Therapeutics Inc.) and more on Quantisnow.